Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Editas Medicine Inc

Healthcare US EDIT

2.99USD
0.21(7.55%)

Last update at 2026-06-04T20:09:00Z

Day Range

2.773.13
LowHigh

52 Week Range

1.294.54
LowHigh

Fundamentals

  • Previous Close 2.78
  • Market Cap322.98M
  • Volume2509287
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-94.05900M
  • Revenue TTM40.52M
  • Revenue Per Share TTM0.46
  • Gross Profit TTM -49.43300M
  • Diluted EPS TTM-1.8

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -160.06000M -237.09300M -153.21900M -220.43200M -192.50200M
Minority interest - - - - -
Net income -160.06000M -237.09300M -153.21900M -204.35200M -185.10700M
Selling general administrative 49.90M 71.99M 69.65M 70.70M 76.18M
Selling and marketing expenses - - - - -
Gross profit 40.52M 32.31M 72.06M 19.71M 25.54M
Reconciled depreciation 5.28M 5.81M 6.17M 6.34M 5.05M
Ebit -153.88900M -238.92000M -169.18100M -225.95000M -193.14600M
Ebitda -148.61200M -233.11100M -163.11700M -219.61300M -188.09300M
Depreciation and amortization 5.28M 5.81M 6.06M 6.34M 5.05M
Non operating income net other - - - 5.52M 0.64M
Operating income -99.33600M -251.15200M -169.18100M -225.95000M -193.14600M
Other operating expenses 139.86M 283.47M 247.30M 245.66M 218.69M
Interest expense 6.17M 2.19M - 4.22M 5.70M
Tax provision - - - - -
Interest income 8.31M 14.06M 13.88M 4.22M 2.34M
Net interest income 2.14M 14.06M 13.88M 4.22M 2.34M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - -16.08000M -7.39500M
Total revenue 40.52M 32.31M 78.12M 19.71M 25.54M
Total operating expenses 139.86M 283.47M 241.24M 245.66M 218.69M
Cost of revenue 5.28M 5.81M 6.06M 6.34M 5.05M
Total other income expense net -60.72400M 14.06M 15.96M 5.52M 0.64M
Discontinued operations - - - - -
Net income from continuing ops -160.06000M -237.09300M -195.08300M -220.43200M -192.50200M
Net income applicable to common shares - - - -220.43200M -192.50200M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 186.53M 341.59M 499.15M 514.32M 677.48M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 2.07M 3.14M 7.53M 7.33M 7.20M
Total liab 159.25M 207.31M 150.06M 153.64M 123.84M
Total stockholder equity 27.29M 134.27M 349.10M 360.68M 553.64M
Deferred long term liab - - - - -
Other current liab -11.89900M 45.86M 34.56M 31.30M 20.19M
Common stock 0.01000M 0.00800M 0.00800M 0.00700M 0.00700M
Capital stock 0.01000M 0.00800M 0.00800M 0.00700M 0.00700M
Retained earnings -1628.50300M -1468.44300M -1231.35000M -1078.13100M -857.69900M
Other liab - - - 60.67M 60.89M
Good will - - - - -
Other assets - - - 5.25M 6.81M
Cash 146.65M 131.54M 123.65M 141.52M 203.52M
Cash and equivalents - - - - -
Total current liabilities 46.25M 77.22M 63.22M 60.11M 46.88M
Current deferred revenue 44.51M 11.22M 8.22M 8.22M 11.33M
Net debt -69.93800M -96.50900M -87.11600M -97.57600M -177.14100M
Short term debt 11.03M 14.65M 12.16M 11.08M 10.31M
Short long term debt - - - - -
Short long term debt total 76.71M 35.03M 36.54M 43.95M 26.38M
Other stockholder equity 1655.78M 1602.44M 1580.24M 1442.40M 1411.83M
Property plant equipment - - - 15.57M 17.12M
Total current assets 163.90M 289.31M 340.83M 356.75M 507.31M
Long term investments - 0.00000M 104.02M 93.10M 120.07M
Net tangible assets - - - 360.68M 553.64M
Short term investments 0.00000M 138.37M 199.46M 202.75M 296.33M
Net receivables 15.18M 16.27M 10.19M 5.14M 0.27M
Long term debt - - - - -
Inventory - - - -93.09700M -120.07000M
Accounts payable 2.60M 5.49M 8.27M 9.51M 5.05M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 0.27M 0.20M -3.60100M -0.49300M
Additional paid in capital - - - - -
Common stock total equity - - - 0.00700M 0.00700M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -1078.13100M -857.69900M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.28M 5.22M 4.71M 5.25M 6.81M
Deferred long term asset charges - - - - -
Non current assets total 22.64M 52.27M 158.32M 157.57M 170.17M
Capital lease obligations 18.10M 35.03M 36.54M 43.95M 26.38M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 139.01M 162.15M -94.09900M 118.17M -46.48900M
Change to liabilities - - - 14.87M -5.30500M
Total cashflows from investing activities 138.67M 162.15M - 114.07M -54.46600M
Net borrowings - - - - -
Total cash from financing activities 40.47M 56.03M 118.04M 1.28M 282.11M
Change to operating activities - - - 12.02M -3.34600M
Net income -160.06000M -237.09300M -153.21900M -220.43200M -192.50200M
Change in cash 13.90M 7.89M -17.87000M -61.99700M 63.84M
Begin period cash flow 135.42M 127.53M 141.52M 207.40M 143.56M
End period cash flow 149.31M 135.42M 123.65M 145.40M 207.40M
Total cash from operating activities -165.24100M -210.28400M -132.17800M -177.34900M -163.80300M
Issuance of capital stock 42.85M 0.00000M 117.08M 0.00100M 249.46M
Depreciation 5.28M 5.81M 6.06M 6.34M 5.05M
Other cashflows from investing activities 0.27M - - 0.02M -
Dividends paid - - - - -
Change to inventory - - - - -3.34600M
Change to account receivables 1.09M -6.07900M -5.04200M -4.87800M 5.78M
Sale purchase of stock - - - 1.28M 282.11M
Other cashflows from financing activities 40.47M 56.03M 0.96M 0.30M 282.11M
Change to netincome - - - 28.57M 45.06M
Capital expenditures 0.61M 8.83M 4.72M 4.12M 7.98M
Change receivables - - - -4.87800M 5.78M
Cash flows other operating - - - -1.81900M -21.88600M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - -61.99700M 63.84M
Change in working capital -31.22900M 3.45M -1.59400M 8.18M -21.41000M
Stock based compensation 10.00M 21.42M 19.80M 29.29M 43.40M
Other non cash items 10.77M -3.86700M -9.76100M -0.72400M 1.66M
Free cash flow -165.84800M -219.11000M -136.89700M -181.46700M -171.78000M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
EDIT
Editas Medicine Inc		 0.21 7.55% 2.99 - - 7.97 11.87 4.82 -1.3579
NVO
Novo Nordisk A/S		 1.75 4.17% 43.75 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.78 4.22% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 13.40 3.13% 441.74 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 9.78 1.58% 628.73 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Editas Medicine Inc

11 Hurley Street, Cambridge, MA, United States, 02141

Key Executives

Name Title Year Born
Mr. James C. Mullen Exec. Chairman 1959
Ms. Michelle Robertson CFO, Principal Accounting Officer, Treasurer & Assistant Sec. 1967
Dr. Mark S. Shearman Exec. VP & Chief Scientific Officer 1960
Dr. Bruce E. Eaton Ph.D. Exec. VP & Chief Bus. Officer 1954
Dr. Gilmore O'Neill Pres & CEO 1964
Dr. Feng Zhang Ph.D. Co-Founder & Scientific Advisory Board Member NA
Dr. George McDonald Church Ph.D. Co-Founder & Scientific Advisory Board Member 1954
Dr. J. Keith Joung M.D., Ph.D. Co-Founder & Scientific Advisory Board Member NA
Dr. David R. Liu Ph.D. Co-Founder & Scientific Advisory Board Member NA
Mr. Harry R. Gill III Sr. VP of Operations 1961

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions